LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LENSAR, Inc. (Nasdaq: LNSR) has announced the granting of stock options to two newly-hired non-executive employees as inducement awards. These options, approved by a majority of independent board members, allow the purchase of a total of 875 shares of the Company's common stock. The grants, made on October 1, 2024, comply with Nasdaq Listing Rule 5635(c)(4).
Key details of the stock options include:
- Exercise price: $4.40 per share (equal to the closing price on the grant date)
- Vesting schedule: 25% after one year, followed by 36 monthly installments
- Term: 10 years
- Subject to LENSAR's 2024 Employment Inducement Incentive Award Plan
LENSAR, Inc. (Nasdaq: LNSR) ha annunciato l'assegnazione di opzioni su azioni a due nuovi dipendenti non esecutivi come premi di incentivazione. Queste opzioni, approvate dalla maggioranza dei membri indipendenti del consiglio, consentono l'acquisto di un totale di 875 azioni delle azioni ordinarie della Società. Le assegnazioni, effettuate il 1 ottobre 2024, sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4).
I dettagli chiave delle opzioni su azioni includono:
- Prezzo di esercizio: $4,40 per azione (corrispondente al prezzo di chiusura alla data di assegnazione)
- Piano di maturazione: 25% dopo un anno, seguito da 36 rate mensili
- Durata: 10 anni
- Oggetto del Piano di Incentivazione per l'Occupazione 2024 di LENSAR
LENSAR, Inc. (Nasdaq: LNSR) ha anunciado la concesión de opciones sobre acciones a dos nuevos empleados no ejecutivos como premios de incentivo. Estas opciones, aprobadas por la mayoría de los miembros independientes de la junta, permiten la compra de un total de 875 acciones de las acciones ordinarias de la compañía. Las concesiones, realizadas el 1 de octubre de 2024, cumplen con la Regla de Inclusión Nasdaq 5635(c)(4).
Los detalles clave de las opciones sobre acciones incluyen:
- Precio de ejercicio: $4.40 por acción (igual al precio de cierre en la fecha de concesión)
- Calendario de adquisición: 25% después de un año, seguido de 36 mensualidades
- Plazo: 10 años
- Sujeto al Plan de Incentivos por Empleo 2024 de LENSAR
LENSAR, Inc. (Nasdaq: LNSR)는 두 명의 신규 비상무 직원에게 유인 수당으로 주식 옵션을 부여한다고 발표했습니다. 이러한 옵션은 독립 이사회의 대다수에 의해 승인되어 회사의 보통주 875주를 구매할 수 있는 권리를 제공합니다. 이 부여는 2024년 10월 1일에 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)에 부합합니다.
주식 옵션의 주요 세부 사항은 다음과 같습니다:
- 행사 가격: $4.40 per share (부여일의 종가와 동일)
- 가치 상승 일정: 1년 후 25%, 이후 36개월 동안 매월 지급
- 유효 기간: 10년
- LENSAR의 2024년 고용 유인 인센티브 상여 계획에 따름
LENSAR, Inc. (Nasdaq: LNSR) a annoncé l'octroi d'options d'achat d'actions à deux nouveaux employés non exécutifs en tant que primes d'incitation. Ces options, approuvées par la majorité des membres indépendants du conseil, permettent l'achat d'un total de 875 actions ordinaires de la société. Les attributions, effectuées le 1er octobre 2024, sont conformes à la règle d'inscription Nasdaq 5635(c)(4).
Détails clés des options d'achat d'actions :
- Prix d'exercice : 4,40 $ par action (correspond au prix de clôture à la date d'octroi)
- Calendrier d'acquisition : 25 % après un an, suivi de 36 mensualités
- Durée : 10 ans
- Sujet au Plan d'Incitation à l'Emploi 2024 de LENSAR
LENSAR, Inc. (Nasdaq: LNSR) hat die Vergabe von Aktienoptionen an zwei neu eingestellte nicht-executive Mitarbeiter als Anreizprämien angekündigt. Diese Optionen, die von der Mehrheit der unabhängigen Vorstandmitglieder genehmigt wurden, ermöglichen den Kauf von insgesamt 875 Aktien des Unternehmens. Die Zuteilungen, die am 1. Oktober 2024 vorgenommen wurden, entsprechen den Nasdaq-Listenregel 5635(c)(4).
Wichtige Details zu den Aktienoptionen umfassen:
- Ausübungspreis: 4,40 $ pro Aktie (entspricht dem Schlusskurs am Zuteilungsdatum)
- Vesting-Plan: 25 % nach einem Jahr, gefolgt von 36 monatlichen Raten
- Laufzeit: 10 Jahre
- Gegenstand des LENSAR 2024 Employment Inducement Incentive Award Plans
- Stock options granted as inducement awards may help attract and retain new talent
- The exercise price of $4.40 per share aligns with the current market value of LENSAR's stock
- Potential dilution of existing shareholders' equity due to the issuance of new stock options
ORLANDO, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock. The options were granted as of October 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY® Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software, with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
| Contacts: | Lee Roth / Cameron Radinovic | |
| Thomas R. Staab, II, CFO | Burns McClellan for LENSAR | |
| ir.contact@lensar.com | lroth@burnsmc.com / cradinovic@burnsmc.com |
FAQ
How many shares of LENSAR (LNSR) stock were granted as options on October 1, 2024?
What is the exercise price of the LENSAR (LNSR) stock options granted on October 1, 2024?
What is the vesting schedule for the LENSAR (LNSR) stock options granted on October 1, 2024?
Under which Nasdaq rule were the LENSAR (LNSR) stock options granted on October 1, 2024?
